ArticleDermatology practical & conceptual2026
The Role of Anti-BP180 Antibody Monitoring in Bullous Pemphigoid: An Italian Single-Center Experience.
Article in Dermatology practical & conceptual, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionBullous pemphigoid (BP) is the most common autoimmune blistering disorder, with anti-BP180 antibodies playing a key role in its pathogenesis and diagnosis. However, their utility in disease monitoring remains debated.
objectivesThis study evaluate the role of anti-BP180 antibody monitoring in BP management through a single-center retrospective analysis and literature review.
methodsWe analyzed 149 BP patients diagnosed between 2014 and 2024 at the Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna. Anti-BP180 titers were measured at baseline, six months, and remission. Therapeutic responses and antibody dynamics were assessed and compared with the literature.
resultsHigher baseline anti-BP180 levels correlated with severe disease and prolonged remission times. A ≥60% reduction in titers was associated with successful therapeutic tapering and lower relapse rates. Patients with secondary BP forms exhibited lower baseline titers and faster remission.
conclusionsAnti-BP180 monitoring serves as a valuable adjunct to clinical assessment, aiding therapeutic decisions, particularly in determining tapering timelines. Nonetheless, integrated approaches combining serological and clinical evaluations remain essential.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.